Looking for Sense in the Italian Antitrust Authority Decision in the Pfizer Xalatan Case
The IAA could find for the existence of the abuse only by misconstruing the very essence of patent law. Daniela Ampollini (Trevisan & Cuonzo)
When requesting a correction, please mention this item's handle: RePEc:cpi:atchrn:7.2.2012:i=7742. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Lindsay McSweeney)
If references are entirely missing, you can add them using this form.